Neurodegeneration

Neurodegenerative diseases are complex, progressive disorders in which molecular and cellular changes translate into measurable changes in brain signaling, behavior and quality of life for patients. There is a current unmet need in the neurodegenerative space for therapeutics that act protectively and/or restoratively. Developing therapies for neurodegenerative disease requires showing the treatment can have a meaningful impact on the complex biology and multifunctional changes associated with disease. Our neurodegenerative portfolio allows for mechanistic and translational models to be assessed on an integrated platform spanning behavior, biomarkers, histology and EEG. This approach addresses disease complexity and allows clients to characterize disease phenotypes, evaluate mechanisms, and use treatment-responsive endpoints to provide translational evidence for advancing promising therapeutics toward the clinic.

Transpharmation supports early and established neurodegeneration programs through integrated preclinical research capabilities that combine mechanism-relevant models, behavioral and functional endpoints, molecular biomarkers, and neuroinflammatory profiling. By evaluating both disease progression and therapeutic response across multiple neurodegenerative indications, we help generate the data needed to support informed development decisions.